Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
The trading up | glenn1919 | investorshub | 09/26/2023 8:39:45 AM |
Price now last up | glenn1919 | investorshub | 09/26/2023 8:36:13 AM |
Have a look at this | Sirpeter | investorshub | 09/26/2023 6:59:39 AM |
Price now | mfayman | investorshub | 09/26/2023 6:00:08 AM |
$OKYO MomentumIts now last trade up | Count Crypto | investorshub | 09/26/2023 5:27:40 AM |
The trading | Pisd | investorshub | 09/26/2023 2:54:37 AM |
$OKYO great article | StocksNcash | investorshub | 09/26/2023 1:21:49 AM |
$OKYO bulls and bears | Count Crypto | investorshub | 09/26/2023 1:12:26 AM |
$OKYO Price now | Monksdream | investorshub | 09/25/2023 11:43:47 PM |
$OKYO MomentumIts trading | Count Crypto | investorshub | 09/25/2023 10:39:21 PM |
$OKYO MomentumIts now last up | mfayman | investorshub | 09/25/2023 8:33:21 PM |
$OKYO Price gaining up | Pisd | investorshub | 09/25/2023 7:46:26 PM |
Price trading | Pisd | investorshub | 09/25/2023 7:29:55 PM |
Price gaining last trade up | Sirpeter | investorshub | 09/25/2023 6:28:25 PM |
$OKYO we got news | Ryguy008 | investorshub | 09/25/2023 4:26:42 PM |
Price gaining | Ryguy008 | investorshub | 09/25/2023 4:00:55 PM |
$OKYO Found an interesting article | Pisd | investorshub | 09/25/2023 2:33:40 PM |
$OKYO MomentumIts now up | Count Crypto | investorshub | 09/25/2023 2:12:35 PM |
$OKYO The gaining up | Pisd | investorshub | 09/25/2023 12:40:15 PM |
$OKYO MomentumIts gaining last trade up | Pisd | investorshub | 09/25/2023 12:25:58 PM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...